Lantheus (NASDAQ:LNTH) Stock Crosses Above 50-Day Moving Average – Time to Sell?

Lantheus Holdings, Inc. (NASDAQ:LNTH)’s stock price passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $100.35 and traded as high as $100.40. Lantheus shares last traded at $100.39, with a volume of 1,330,006 shares changing hands.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent analyst reports. Mizuho restated a “neutral” rating and issued a $109.00 price objective (down from $115.00) on shares of Lantheus in a report on Tuesday, October 13th. CJS Securities lowered shares of Lantheus from a “market outperform” rating to a “market perform” rating in a research report on Tuesday, August 4th. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their target price for the company from $110.00 to $102.50 in a research report on Monday, August 3rd. Finally, William Blair set a $102.50 price objective on Lantheus in a research note on Monday, August 3rd. Three analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $107.44.

Lantheus Stock Down 0.1%

The stock’s fifty day simple moving average is $100.32 and its two-hundred day simple moving average is $98.58. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The company has a market capitalization of $6.54 billion, a price-to-earnings ratio of 20.13 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%. The business had revenue of $388.18 million for the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the business earned $1.57 earnings per share. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.54 EPS for the current year.

Institutional Investors Weigh In On Lantheus

Large investors have recently made changes to their positions in the business. ABS Investment Management LLC purchased a new position in shares of Lantheus in the 2nd quarter worth about $232,974,000. Western Wealth Management LLC purchased a new position in Lantheus in the 1st quarter worth approximately $25,000. USA Financial Formulas purchased a new position in Lantheus in the third quarter worth about $41,000. Allworth Financial LP bought a new position in shares of Lantheus in the second quarter worth about $49,000. Finally, Bessemer Group Inc. lifted its holdings in Lantheus by 221.2% during the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 354 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.

The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.